• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following list of names for the drugs described are "under consideration" by the USAN Council:

January 2016

avadomide antineoplastic
baltaleucel-T treatment lymphoma
berzopatrib treatment of solid tumors
dolvetmab treatment of cancer, veterinary indications, immunomodulatory
extelumab treatment of rheumatoid arthritis
farginostat antineoplastic
fosmetpantothenate treatment of pantothenate kinase associated neurodegeneration
frinezumab treatment of progressive supranuclear palsy (PSP)
galmanezumab treatment of macular degeneration
gednezumab treatment of progressive supranuclear palsy (PSP)
iberdomide antineoplastic
lanabecestat treatment of Alzheimer's disease; inhibition of amyloid beta
neflamapimod immunomodulator and treatment of Alzheimer's disease
oleclumab treatment of pancreatic and colorectal cancer
samigenlecleucel-T cellular therapy; antineoplastic
telocantel anthelmintic
tesidorsen treatment of acromegaly
valtramiprostate treatment of Alzheimer's disease
veldotide treatment of acromegaly

December 2015

lexinidase alfa treatment of Sanfilippo's syndrome

November 2015

allopregnanolone treatment of refractory status epilepticus (RSE)
axileugencel-T antineoplastic; cellular therapy
citarinostat treatment of hematologic malignacies
dezapelisib treatment of hematologic malignancies
fenevetmab treatment of osteoarthritis pain in cats
mardecamp treatment of Huntington’s disease
mardecamprin treatment of Huntington’s disease
midmafetamine adjunct to psychotherapy in the treatment of PTSD
rebaxamase preventing side effects associated with IV administration of β-lactam antibiotics